Open Access

Peer-reviewed

Case Report

Main Article Content

Abdul Rehman Farooq corresponding author
Clodagh Keohane
Maeve Crowley
Laura Whelan
Neasa Gallwey
Claire Brady
Seamus O'Reilly

Abstract

Autoimmune haemolytic anemia is a rare but potentially catastrophic adverse event of im-mune checkpoint inhibitor therapy. We present the case of a gentleman who presented with non-specific symptoms while undergoing adjuvant Nivolumab therapy after potential-ly curative surgery for gastroesophageal cancer. The patient’s haemoglobin deteriorated to 4.7 g/dl with no evidence of bleeding and serologic tests indicative of hemolysis. He re-ceived emergent massive RCC transfusion receiving 9 units of bloods in 1 night, and was commenced on high dose methylprednisolone. During subsequent weeks of inpatient care, the patient continued to received multiple daily red cell transfusions and had a total of 53 RCC transfusions during admission, along with high doses of steroids,4 doses of weekly Rituximab as well as 2 doses of IVIG.While he was discharged on day 38 of admission, he required a slow taper of steroids over 6 months. Immune related hemolytic anemias are a rare corollary of immune check point inhibitors. The cases of immune related AIHA docu-mented in the literature were treated with steroids, Rituximab and IVIG, which are also rec-ommended by guidelines for the treatment of immune related haemolytic anemias.

Keywords
autoimmune haemolytic anemia, Nivolumab, hemolysis, hematologic toxicity, immunotherapy, immune related toxicity

Article Details

Supporting Agencies
The clinical trials unit is funded through the Health Research Board (Project No. CTIC- 2021-002), UCC Cancer Trials Group, University College Cork, HRB Cancer Trials in Ireland, 2021.
How to Cite
Farooq, Abdul Rehman, Clodagh Keohane, Maeve Crowley, Laura Whelan, Neasa Gallwey, Claire Brady, and Seamus O’Reilly. 2022. “A Case of Life Threatening Acute Nivolumab Induced Autoimmune Haemolytic Anaemia”. Current Cancer Reports 4 (1), 133-38. https://doi.org/10.25082/CCR.2022.01.002.

References

  1. Abdel-Rahman O, Eltobgy M, Oweira H, et al. Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review. Immunotherapy, 2017, 9(14): 1175-1183. https://doi.org/10.2217/imt-2017-0108
  2. Kuswanto WF, MacFarlane LA, Gedmintas L, et al. Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. Seminars in Arthritis and Rheumatism, 2018, 47(6): 907-910. https://doi.org/10.1016/j.semarthrit.2017.10.018
  3. Khoja L, Day D, Chen WW, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review - ScienceDirect. Annals of Oncology, 2017, 28(10): 2377-2385. https://doi.org/10.1093/annonc/mdx286
  4. Tanios GE, Doley PB and Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. European Journal of Haematology, 2019, 102(2): 157-162. https://doi.org/10.1111/ejh.13187
  5. Delanoy N, Michot JM, Comont T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol, 2019, 6(1): e48-e57. https://doi.org/10.1016/S2352-3026(18)30175-3
  6. Davis EJ, Salem J, Young A, et al. Hematologic Complications of Immune Checkpoint Inhibitors. The Oncologist, 2019, 24(5): 584-588. https://doi.org/10.1634/theoncologist.2018-0574
  7. Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncology, 2015, 16(9): 1090-1098. https://doi.org/10.1016/S1470-2045(15)00040-6
  8. 2018 ASCO Guidelines on management of immune related adverse events. Accessed 05/11/2021. https://www.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/2018-ma nagement-of-irAEs-summary.pdf
  9. Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood, 2014, 124(19): 2930-2936. https://doi.org/10.1182/blood-2014-06-583021
  10. Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program, 2009, 2009(1): 73-79. https://doi.org/10.1182/asheducation-2009.1.73
  11. Brodsky RA. Warm Autoimmune Hemolytic Anemia. New England Journal of Medicine, 2019, 381(7): 647-654. https://doi.org/10.1056/NEJMcp1900554
  12. Hill A and Hill QA. Autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program, 2018, 2018(1): 382-389. https://doi.org/10.1182/asheducation-2018.1.382
  13. Berentsen S and Barcellini W. Autoimmune Hemolytic Anemias. New England Journal of Medicine, 2021, 385(15): 1407-1419. https://doi.org/10.1056/NEJMra2033982
  14. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39(36): 4073-4126. https://doi.org/10.1200/JCO.21.01440
  15. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. New England Journal of Medicine, 2021, 384(13): 1191-1203. https://doi.org/10.1056/NEJMoa2032125